Literature DB >> 6383499

Busulfan and total body irradiation as antihematopoietic stem cell agents in the preparation of patients with congenital bone marrow disorders for allogenic bone marrow transplantation.

R Parkman, J M Rappeport, S Hellman, J Lipton, B Smith, R Geha, D G Nathan.   

Abstract

The capacity of busulfan and total body irradiation to ablate hematopoietic stem cells as preparation for the allogeneic bone marrow transplantation of patients with congenital bone marrow disorders was studied. Fourteen patients received 18 transplants; busulfan was used in the preparatory regimen of eight transplants and total body irradiation in the regimens of six transplants. Sustained hematopoietic ablation was achieved in six of eight patients prepared with busulfan and in all six patients prepared with total body irradiation. Three patients prepared with total body irradiation died with idiopathic interstitial pneumonitis, whereas no patients receiving busulfan developed interstitial pneumonitis. The optimal antihematopoietic stem cell agent to be used for the preparation of patients with congenital bone marrow disorder for bone marrow transplantation is not certain.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6383499

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  B lymphocyte reconstitution after human bone marrow transplantation. Leu-1 antigen defines a distinct population of B lymphocytes.

Authors:  J H Antin; K A Ault; J M Rappeport; B R Smith
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

Review 2.  The role of busulfan in bone marrow transplantation.

Authors:  M Hassan
Journal:  Med Oncol       Date:  1999-09       Impact factor: 3.064

3.  Contribution of bone marrow hematopoietic stem cells to adult mouse inner ear: mesenchymal cells and fibrocytes.

Authors:  Hainan Lang; Yasuhiro Ebihara; Richard A Schmiedt; Hitoshi Minamiguchi; Daohong Zhou; Nancy Smythe; Liya Liu; Makio Ogawa; Bradley A Schulte
Journal:  J Comp Neurol       Date:  2006-05-10       Impact factor: 3.215

4.  Pharmacokinetic and metabolic studies of busulfan in rat plasma and brain.

Authors:  M Hassan; H Ehrsson; I Wallin; S Eksborg
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1988 Oct-Dec       Impact factor: 2.441

5.  Bone marrow transplantation (BMT) for the syndrome of pigmentary dilution and lymphohistiocytosis (Griscelli's syndrome).

Authors:  L C Schneider; R S Berman; C R Shea; A R Perez-Atayde; H Weinstein; R S Geha
Journal:  J Clin Immunol       Date:  1990-05       Impact factor: 8.317

6.  Pharmacokinetic and metabolic studies of high-dose busulphan in adults.

Authors:  M Hassan; G Oberg; H Ehrsson; M Ehrnebo; I Wallin; B Smedmyr; T Tötterman; S Eksborg; B Simonsson
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

7.  Pharmacokinetics of high-dose busulfan in children.

Authors:  G Vassal; A Gouyette; O Hartmann; J L Pico; J Lemerle
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

8.  Prospective validation of a novel dosing scheme for intravenous busulfan in adult patients undergoing hematopoietic stem cell transplantation.

Authors:  Sang-Heon Cho; Jung-Hee Lee; Hyeong-Seok Lim; Kyoo-Hyung Lee; Dae-Young Kim; Sangmin Choe; Kyun-Seop Bae; Je-Hwan Lee
Journal:  Korean J Physiol Pharmacol       Date:  2016-04-26       Impact factor: 2.016

Review 9.  Pulmonary Toxicity After Total Body Irradiation - Critical Review of the Literature and Recommendations for Toxicity Reporting.

Authors:  Jennifer Vogel; Susanta Hui; Chia-Ho Hua; Kathryn Dusenbery; Premavarthy Rassiah; John Kalapurakal; Louis Constine; Natia Esiashvili
Journal:  Front Oncol       Date:  2021-08-26       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.